Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Hold at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a sell rating to a hold rating in a research report sent to investors on Thursday morning, BidAskClub reports.

Several other equities analysts have also recently commented on NTLA. Zacks Investment Research cut shares of Intellia Therapeutics from a buy rating to a hold rating in a research report on Thursday, August 8th. Robert W. Baird assumed coverage on shares of Intellia Therapeutics in a research report on Monday, July 8th. They issued an outperform rating and a $23.00 target price for the company. Roth Capital assumed coverage on shares of Intellia Therapeutics in a research report on Monday, June 10th. They issued a neutral rating and a $16.00 target price for the company. Chardan Capital restated a buy rating and issued a $57.50 target price on shares of Intellia Therapeutics in a research report on Tuesday, May 28th. Finally, ValuEngine cut shares of Intellia Therapeutics from a buy rating to a hold rating in a research report on Monday, August 26th. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of $25.56.

Shares of NASDAQ:NTLA traded down $0.50 during midday trading on Thursday, hitting $14.25. The stock had a trading volume of 33,282 shares, compared to its average volume of 474,782. The company’s 50-day moving average price is $16.25 and its 200-day moving average price is $16.04. The company has a market capitalization of $724.40 million, a P/E ratio of -7.20 and a beta of 2.71. The company has a quick ratio of 7.99, a current ratio of 7.99 and a debt-to-equity ratio of 0.05. Intellia Therapeutics has a fifty-two week low of $11.03 and a fifty-two week high of $32.95.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, August 1st. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.05. The company had revenue of $11.10 million during the quarter, compared to analysts’ expectations of $7.15 million. Intellia Therapeutics had a negative net margin of 242.65% and a negative return on equity of 33.03%. The business’s revenue for the quarter was up 44.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.52) EPS. Research analysts expect that Intellia Therapeutics will post -2.29 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Benjamin Edwards Inc. increased its position in Intellia Therapeutics by 60.9% during the 2nd quarter. Benjamin Edwards Inc. now owns 1,691 shares of the company’s stock worth $28,000 after purchasing an additional 640 shares in the last quarter. Tortoise Investment Management LLC increased its position in Intellia Therapeutics by 100.0% during the 1st quarter. Tortoise Investment Management LLC now owns 2,000 shares of the company’s stock worth $34,000 after purchasing an additional 1,000 shares in the last quarter. Bank of Montreal Can increased its position in Intellia Therapeutics by 406.5% during the 2nd quarter. Bank of Montreal Can now owns 3,824 shares of the company’s stock worth $63,000 after purchasing an additional 3,069 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new position in Intellia Therapeutics during the 2nd quarter worth approximately $64,000. Finally, Aperio Group LLC acquired a new position in Intellia Therapeutics during the 2nd quarter worth approximately $83,000. Institutional investors and hedge funds own 79.39% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

Read More: How to Calculate Compound Annual Growth Rate (CAGR)

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.